ReviewBiotechnology advances
Rigid nanoparticle-based delivery of anti-cancer siRNA: challenges and opportunities.
Review in Biotechnology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 81 citations in OpenAlex.
- Small interfering RNA (siRNA)-based targeting breast cancer therapy.Discover oncology · 2026Review
- Nanoparticles and Nanocarriers for Managing Plant Viral Diseases.Plants (Basel, Switzerland) · 2025Review
- Nanocarrier-Based Eco-Friendly RNA Pesticides for Sustainable Management of Plant Pathogens and Pests.Nanomaterials (Basel, Switzerland) · 2024Review
- The role of polymers in enabling RNAi-based technology for sustainable pest management.Nature communications · 2024Review
- Nucleic Acid Armor: Fortifying RNA Therapeutics through Delivery and Targeting Innovations for Immunotherapy.International journal of molecular sciences · 2024Review
- Bench-to-bedside development of multifunctional flexible embolic agents.Theranostics · 2023Review
- Pharmacodynamics and pharmacokinetics of PLGA-based doxorubicin-loaded implants for tumor therapy.Drug delivery · 2022Article
- Biocompatible Iron Oxide Nanoparticles for Targeted Cancer Gene Therapy: A Review.Nanomaterials (Basel, Switzerland) · 2022Review
- Delivery of therapeutic small interfering RNA: The current patent-based landscape.Molecular therapy. Nucleic acids · 2022Article
- The Progress and Promise of RNA Medicine─An Arsenal of Targeted Treatments.Journal of medicinal chemistry · 2022Review
- Inorganic Nanomaterial-Mediated Gene Therapy in Combination with Other Antitumor Treatment Modalities.Advanced functional materials · 2021Article
- Self-assembled Viral Nanoparticles as Targeted Anticancer Vehicles.Biotechnology and bioprocess engineering : BBE · 2021Review
- TAT-Modified Gold Nanoparticles Enhance the Antitumor Activity of PAD4 Inhibitors.International journal of nanomedicine · 2020Article
- Bioconjugated Carbon Dots for Delivery of siTnfα to Enhance Chondrogenesis of Mesenchymal Stem Cells by Suppression of Inflammation.Stem cells translational medicine · 2019Article
- Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.Drug design, development and therapy · 2019Article
- Targeted delivery of HES5-siRNA with novel polypeptide-modified nanoparticles for hepatocellular carcinoma therapy.RSC advances · 2018Article
- The Daniel K. Inouye College of Pharmacy Scripts: Targeted Nanocarrier Based Systems for the Treatment of Lung Cancer.Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health · 2017Review
- Tackling breast cancer chemoresistance with nano-formulated siRNA.Gene therapy · 2016Review
- Ligand-targeted theranostic nanomedicines against cancer.Journal of controlled release : official journal of the Controlled Release Society · 2016Review
- Calcium phosphate nanoparticles-based systems for siRNA delivery.Regenerative biomaterials · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Gene therapy is a promising strategy to treat various genetic and acquired diseases. Small interfering RNA (siRNA) is a revolutionary tool for gene therapy and the analysis of gene function. However, the development of a safe, efficient, and targetable non-viral siRNA delivery system remains a major challenge in gene therapy. An ideal delivery system should be able to encapsulate and protect the siRNA cargo from serum proteins, exhibit target tissue and cell specificity, penetrate the cell membrane, and release its cargo in the desired intracellular compartment. Nanomedicine has the potential to deal with these challenges faced by siRNA delivery. The unique characteristics of rigid nanoparticles mostly inorganic nanoparticles and allotropes of carbon nanomaterials, including high surface area, facile surface modification, controllable size, and excellent magnetic/optical/electrical properties, make them promising candidates for targeted siRNA delivery. In this review, recent progresses on rigid nanoparticle-based siRNA delivery systems will be summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.